Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Cell Metab. 2020 Jul 28;32(3):353–365.e8. doi: 10.1016/j.cmet.2020.07.002

Figure 2. SRI-37330 acts via a distinct E-box motif in the TXNIP promoter.

Figure 2

(a) Effects of SRI-37330 on the activity of the full-length (FL-1518) human TXNIP promoter, the D-420 and D-400 deletions and the mutD-400 E-box mutation as assessed by dual luciferase assays and compared to no SRI-37330 control, FL-1518 (*P = 0.0275); D-420 (*P = 0.0010); D-400 (*P = 0.0157); mutD-400 (N.S. not significant); mean ± s.e.m, n = 3 independent experiments.

(b) Effects of SRI-37330 on relative luciferase activity driven by a SV40 control promoter (N.S.) or the SV40 promoter coupled with the TXNIP-E-box motif (F3, 20 =17.82,*P< 0.0001), n = 6 independent experiments.

(c) Chromatin immunoprecipitation (ChIP) analysis of polymerase II (Pol II) binding to the TXNIP promoter in the E-box motif region (TXNIP E-box t4 = 2.88, *P = 0.0451), an upstream promoter region (TXNIP Upstream, N.S.) and an established Pol II binding site in the insulin receptor substrate 2 (IRS2, N.S.) in response to SRI-37330, n = 3 independent experiments.